Ascelia Pharma gets US patent for 2nd generation Mangoral
Ascelia Pharma AB (publ) (ticker: ACE) today announced that the US Patent Office (USPTO) has issued a new patent covering a second-generation formulation of lead drug candidate Mangoral, currently in the pivotal Phase 3 study SPARKLE. The new patent further improvesthe unique value proposition of the Mangoral franchise and provides patent protection until year 2040 in the US. The opportunity to improve the Mangoral product and add patent protection rights add significant value to Ascelia Pharma’s Mangoral franchise. With the new patent, the protection rights are further strengthened until year 2040 in the US.
Press inquiries should be adressed to: